Plain-English translation of NCT06109207 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing whether combining two medications— (an immunotherapy drug) and Dalpiciclib (a targeted cancer drug)—can work better together to treat head and neck cancer before surgery. The study will give you two doses of by IV infusion every three weeks, along with daily Dalpiciclib pills for eight weeks total, before your planned surgery.
Standard chemotherapy for head and neck cancer has helped some patients, but doctors believe combining an immunotherapy drug with a targeted drug might work better by helping your immune system recognize and fight cancer cells more effectively.
You will receive by IV infusion on day 1 of every three-week cycle for two cycles (six weeks total) before your surgery. At the same time, you'll take Dalpiciclib pills by mouth daily for eight weeks, following a schedule of three weeks on and one week off. The study team will monitor you closely with blood tests and check-ups to watch for side effects. After completing the two medication cycles, you will proceed to surgery as planned.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
West China Hospital
Enrollment target
~6 participants
Started
October 2023
Primary completion
October 2024
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jin Zhou, MD.,PhD.
West China Hospital